← All trials
NCT04179604
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2019
- Primary completion
- Jan 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Mario Negri InstituteLead sponsor
- Orion CorporationCollaborator
- Mario Negri InstituteSponsor investigator
- Canary FoundationCollaborator
- University of SevilleOverall official - principal investigator
- University of MalagaOverall official - principal investigator
- University of ValladolidOverall official - principal investigator
- QBE Europe SA/NVCollaborator
- Autonomous University of MadridOverall official - principal investigator
- Badalona Hospital Germans Trias i PujolOverall official - principal investigator
- Mario Negri InstituteOverall official - principal investigator
- Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaOverall official - principal investigator
- TRIDE Asesores SLCollaborator
- University of CorunaOverall official - principal investigator
- Universidad Complutense de MadridOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.